Emcure Pharma IPO Details
Issue Date
03 Jul - 5 Jul'24
Price Range
₹960 - ₹1008
Lot Size
14
IPO Size
₹1953.01 Cr
Emcure Pharma IPO Listing Details
Listing On
10 Jul'24
Issue Price
₹1008
Listed Price
₹ 1325.05
Retail Gain/Listing Gain
▲31.45%
Schedule of Emcure Pharma IPO
Start date
03/07/2024
End date
05/07/2024
Allotment of bids
Refund Initiation
09/07/2024
Listing on exchange
10/07/2024
Emcure Pharmaceuticals IPO Review | Issue details, financials, products | Namita Thapar | Must watch
Kotak Neo
•4m 16s
Emcure Pharmaceuticals Company Background
Emcure Pharmaceuticals is an Indian pharmaceutical company that develops, manufactures and globally markets a broad range of pharmaceutical products across several major therapeutic areas.
It is a research and development (R&D) driven company with a differentiated product portfolio that includes orals, injectables and biotherapeutics, which enables them to reach a range of target markets across over 70 countries, with a strong presence in India, Europe and Canada.
With that, let's take a look at the competitive strengths and risk factors for Emcure Pharmaceuticals Limited:
Emcure Pharmaceuticals Competitive Strengths
Well-placed to leverage their position in the domestic market
The company is focused on the domestic market, with sales in India contributing 48.28% of their total revenue for FY24. Since shifting their focus to Indian domestic branded generics in 1995, they have grown significantly. They are now the 13th largest pharmaceutical company in India by Domestic Sales for MAT FY24, the 4th largest by market share in their covered markets, and the largest in the gynecology and HIV antivirals therapeutic areas in India (Source: CRISIL Report).
Demonstrated capabilities of building brands
They have demonstrated strong capabilities and a proven track record in building brands. Six of their brands were ranked among the 300 highest-selling brands in the IPM in terms of Domestic Sales for MAT Financial Year 2024 (Source: CRISIL Report). Additionally, 16 of their top 20 brands were each ranked among the three highest-selling brands in their respective therapeutic areas in the IPM for the same period (Source: CRISIL Report).
Large, diversified and fast-growing product portfolio in international markets
They sell their portfolio of products in over 70 countries, with Europe and Canada being their primary international markets. Sales outside India contributed 51.72% of their total revenue for the FY24.
Emcure Pharma Risk Factors
-
Any manufacturing or quality control problems may damage the company’s reputation and subject them to regulatory action, which could adversely affect the business.
-
Failure to comply with applicable quality standards may result in product liability claims, which could adversely affect the business, financial condition, cash flows and results of operations.
-
Any disruptions to the supply, or an increase in the pricing of raw materials and finished products that are outsourced, may adversely affect the business, cash flows, financial condition and results of operations.
Key Strategies
-
Increase market share in the domestic market.
-
Continue to invest in R&D and manufacturing capabilities to enhance and grow their differentiated product portfolio.
-
Pursue strategic acquisitions, partnerships and in-licensing arrangements.
Emcure Pharma Key Financials
Here are the key financials for Emcure Pharmaceuticals Limited:
How to apply for IPO through ASBA
Kotak Neo
•04m 01s
How To Apply for Emcure Pharmaceuticals Ltd IPO?
Here are the steps to apply for Emcure Pharmaceuticals Ltd IPO:
Step 1: Log in to your Kotak Neo Demat account Log in to your Demat account to access IPO investments. Next, select the current IPO section.
Step 2: Specify IPO details Enter the number of lots and the price you wish to apply for.
Step 3: Enter UPI ID After entering your UPI ID, click submit. This will place your bid with the exchange.
Step 4: Mandate Notification Your UPI app will receive a mandate notification to block funds.
Step 5: Approve Request Your funds will be blocked once you approve the mandate request on your UPI.
Emcure Pharma IPO FAQs
The Emcure Pharma IPO opens for subscription from 03-07-2024 to 05-07-2024, with a total issue size of ₹1953.01 Cr. The IPO price band is ₹960 to ₹1008 per share with a lot size of 14. The company aims to list the shares on BSE & NSE on 10-07-2024.
The Emcure Pharma IPO will open for subscription on 03-07-2024 and will close on 05-07-2024 for investors.
The minimum lot size for the Emcure Pharma IPO is 14 equity shares, requiring a minimum investment of ₹14112 for retail investors applying in the IPO.
The price band of the Emcure Pharma IPO has been fixed at ₹960 to ₹1008 per equity share.
You can apply for the Emcure Pharma IPO online through the Kotak Neo Website or the Kotak Neo App using UPI or ASBA during the IPO subscription period.
Emcure Pharma IPO allotment will take place on [-].
You can check the Emcure Pharma IPO allotment status online on the registrar’s website or on the NSE and BSE IPO allotment pages using your application number, PAN, or demat account details.
Emcure Pharma shares will list on the stock exchanges on 10-07-2024.
You can find detailed information about the Emcure Pharma IPO, including its business operations, financial performance, risk factors, and IPO objectives, in the Draft or Red Herring Prospectus (RHP).
The Emcure Pharmaceuticals Limited IPO has an issue size of Rs. 1,952 crores. The IPO opens for subscription on 3rd July 2024 and closes on 5th July 2024
Link Intime India Private Limited is the registrar for this IPO.
Opening of account will not guarantee allotment of shares in IPO. Investors are requested to do their own due diligence before investing in any IPO.
Trending IPOs
30 Apr - 05 May'26 | |||||||||
05 May - 07 May'26 | |||||||||
05 May - 07 May'26 | |||||||||
04 May - 06 May'26 | |||||||||
To be announced | |||||||||
Trending IPOs
30 Apr - 05 May'26 | |||||||||
05 May - 07 May'26 | |||||||||
05 May - 07 May'26 | |||||||||
04 May - 06 May'26 | |||||||||
To be announced | |||||||||